Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

China flag China · Delayed Price · Currency is CNY
8.42
+0.07 (0.84%)
At close: Jun 18, 2026
Market Cap18.78B -34.4%
Revenue (ttm)4.41B -20.2%
Net Income591.52M -55.7%
EPS0.26 -56.4%
Shares Out 2.23B
PE Ratio32.19
Forward PE20.54
Dividend0.17 (2.05%)
Ex-Dividend DateApr 29, 2026
Volume9,246,882
Open8.38
Previous Close8.35
Day's Range8.26 - 8.51
52-Week Range8.25 - 12.94
Beta0.02
AnalystsStrong Buy
Price Target14.00 (+66.27%)
Earnings DateAug 18, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,126
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301301
Full Company Profile

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.

Financial Statements